The B4GALNT1 antibody targets the β-1.4-N-acetylgalactosaminyltransferase 1 enzyme, encoded by the *B4GALNT1* gene. This enzyme catalyzes the transfer of N-acetylgalactosamine (GalNAc) to glycoproteins and glycolipids, playing a key role in synthesizing Sda blood group antigens and related glycoconjugates. B4GALNT1 is expressed in various tissues, including the gastrointestinal tract, kidneys, and brain, and its dysregulation has been implicated in diseases such as cancer and neurological disorders.
In research, B4GALNT1 antibodies are widely used to study protein expression, localization, and function. They help investigate the enzyme's role in cell adhesion, signaling, and tumor progression. For example, reduced B4GALNT1 expression correlates with poor prognosis in colorectal and ovarian cancers, suggesting its potential as a biomarker. Conversely, elevated levels are observed in certain neurodegenerative conditions, highlighting its diverse pathological relevance.
Antibodies against B4GALNT1 are available as monoclonal or polyclonal forms, optimized for techniques like Western blotting, immunohistochemistry (IHC), and immunofluorescence (IF). Their specificity is critical for distinguishing B4GALNT1 from related glycosyltransferases. Recent studies also explore therapeutic applications, such as targeting glycans in cancer immunotherapy. Overall, B4GALNT1 antibodies serve as essential tools for unraveling glycobiology mechanisms and advancing diagnostic or therapeutic strategies.